This Popular Dog Medicine Just Got Pulled: Here’s What Was Found Inside

Pet product recalls in 2026 have ranged from contaminated foods to mislabeled veterinary items, putting more scrutiny on products that reach animals through clinics, pharmacies, and retail channels. The latest action centers on Adequan Canine, a prescription joint treatment widely used for dogs with degenerative or traumatic joint problems. American Regent, Inc. Animal Health announced the recall after internal testing found glass fiber material in specific lots.

American Regent pulled two lots of Adequan Canine after testing found glass fibers

American Regent, Inc. Animal Health announced on July 31, 2026, that it was conducting a nationwide recall of two lots of Adequan Canine Injection for dogs to the consumer level, according to the company notice posted by the FDA on August 3. The recalled product is Adequan Canine Injection, 100 mg/mL, in 5 mL multi-dose vials, lot numbers 3369 and 25011. The company said the recall was prompted by the presence of glass fibers found during testing of internally retained samples.

The FDA’s animal-veterinary recalls page lists the action under its August 3, 2026 entries and describes the reason as visible glass fiber material in the product. Adequan Canine is a prescription medication used for non-infectious degenerative or traumatic joint dysfunction in dogs, and the product is administered by intramuscular injection under the direction of a licensed veterinarian. American Regent said it had not received reports of adverse events tied to the recalled dog lots as of the announcement date.

The company’s notice also gives product-specific details. Lot 3369 was distributed on May 22, 2024, with an expiration date of October 31, 2026, and lot 25011 was distributed on April 14, 2025, with an expiration date of December 31, 2027. The recall notice posted by FDA does not list an FDA enforcement recall number such as an “F-” designation, and no hazard classification such as Class I, Class II, or Class III was stated in the public announcement.

The recall is nationwide, but no state-by-state distribution list has been released

American Regent said the recalled Adequan Canine lots were distributed nationwide in the United States to online pharmacies, distributors, wholesalers, and veterinarians. Because the company described the distribution as nationwide rather than by a limited shipping map, the affected area includes Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming.

What has not been released is a state-by-state breakdown of shipments or a public list of specific clinics, pharmacies, or veterinary hospitals that received the recalled lots. The company also has not published city-level distribution details. That means pet owners may know the product was sold in the United States, but they may not be able to confirm affected local providers without checking the lot number directly.

The recall guidance is specific. American Regent said any person or entity with the recalled product lots should not use them. Consumers were told to stop using the recalled lots and contact their veterinarian if their pets experienced any problems that may be related to the product, while distributors, retailers, hospitals, and clinics were instructed to return unused product to the manufacturer or discard it.

The concern is particulate contamination in an injectable drug, not a labeling issue

The reason for the recall is not a packaging typo or a potency question. American Regent said the lots are being recalled because glass fibers were found during testing of retained samples, making this a particulate contamination issue in an injectable veterinary drug. In the company’s risk statement, intramuscular injection of material containing glass fibers may result in local irritation, swelling, inflammation, injection-site pain, infection, or abscesses.

That context matters because Adequan Canine is not an over-the-counter chew or supplement. It is a prescription injection used in veterinary practice, which means the product typically moves through clinics and pharmacy channels rather than general store shelves. The FDA notice states that the drug is intended to be used by or under the direction of a licensed veterinarian, and the company’s instructions focus on immediate discontinuation of the recalled lots rather than broader removal of the entire product line.

For customers, the practical takeaway is narrow but important: only Adequan Canine 100 mg/mL 5 mL multi-dose vials from lot 3369 or 25011 are included in this recall, and no other Adequan Canine lots were named in the public notice. American Regent said the recall is being conducted with the knowledge of the FDA and stated that it is taking the precautionary action to protect public health while customer service handles returns, replacements, and related questions.